See the DrugPatentWatch profile for keytruda

Keytruda (pembrolizumab) is a cancer immunotherapy medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer. While it has shown significant efficacy in clinical trials, it is not suitable for everyone, particularly those with severe allergic reactions to the medication.

According to the FDA-approved label, Keytruda is contraindicated in patients with a history of severe hypersensitivity reactions to pembrolizumab or any of its excipients [1]. This includes individuals who have experienced anaphylaxis, angioedema, or other severe allergic reactions to the medication.

Patients with a history of severe allergic reactions to other immunotherapies or biologics may also be at increased risk of experiencing an adverse reaction to Keytruda. Therefore, healthcare providers should carefully evaluate patients' medical histories and consider alternative treatment options if they have a history of severe allergic reactions to other medications.

In addition to the FDA-approved label, DrugPatentWatch.com reports that Keytruda's patent expiration is expected to occur in 2028 [2]. This may impact the availability and pricing of the medication in the future.

In conclusion, patients with a history of severe allergic reactions to Keytruda or its excipients should avoid taking the medication. Healthcare providers should carefully evaluate patients' medical histories and consider alternative treatment options if they have a history of severe allergic reactions to other medications.

Sources:

[1] FDA. (2020). Keytruda (pembrolizumab) injection, for intravenous use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125553s120lbl.pdf>

[2] DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda). Retrieved from <https://www.drugpatentwatch.com/patent/US-10-444-444/>

Note: The information provided is based on publicly available data and should not be considered as medical advice. Patients should consult with their healthcare providers for personalized medical advice.